Medindia

X

Echo Therapeutics Announces Research Initiation by LifeTech Capital

Friday, January 22, 2010 General News J E 4
Advertisement

FRANKLIN, Mass., Jan. 22 /PRNewswire-FirstCall/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing the needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, is pleased to announce the availability of an independent research report that was issued yesterday with a "Strong Speculative Buy" recommendation and a 12 to 18 month price target of $4.50. The report is authored by Stephen M. Dunn, Senior Managing Director, Research, and William D. Dawson, Senior Vice President, Research, for LifeTech Capital, a division of Aurora Capital LLC. It can be found online at www.lifetechcapital.com/reports.htm.

The report describes Echo's commercialization strategy, outlines the analysts' views of Echo's market opportunity, and includes the analysts' estimates for Echo's future financial performance. Echo Therapeutics is making this announcement as a service to its shareholders and is not endorsing the report nor commenting on its contents.

About Echo Therapeutics

Echo is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System for transdermal drug delivery of a wide range of novel topical reformulations of widely-used, FDA-approved products.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's and its partners' ongoing studies, including the efficacy of the Symphony tCGM System and Prelude SkinPrep System, the failure of future development and preliminary marketing efforts related to the Symphony tCGM System and Prelude SkinPrep System, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM System and Prelude SkinPrep System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to the Symphony tCGM System and the Prelude SkinPrep System. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-K for the year ended December 31, 2008, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. Echo Therapeutics, Inc. undertakes no obligation to publicly update or revise any forward-looking statements.

www.echotx.com

© 2002 - 2010 Echo Therapeutics, Inc. All rights reserved worldwide.

SOURCE Echo Therapeutics, Inc.

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Cardica to Announce Fiscal 2010 Second Quarter Fin...
S
BNA Books' New 2009 Cumulative Supplement to 'Heal...